Showing 5 of 17 posts
June 2, 2021 | Blogs
The recently introduced Medical Fund Bill has potential to improve access to novel therapies applying for reimbursement in Poland, however, it is yet to be seen how the criteria for inclusion in the Fund’s list are clarified locally and whether a broader scope of therapies will be eligible for the scheme to deem the market more attractive for submissions.
October 29, 2020 | Blogs
An analysis of the key drug pricing proposals in the 2020 USA Election in terms of political focus, party priorities, implementation feasibility, and potential risk to biopharma.
October 20, 2020 | Blogs
Pharma and biotech companies should be prepared to make long-term investments in capability building, market development, and evidence generation to maximize the value of digital companions.
September 22, 2020 | Blogs
CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.
August 5, 2020 | Blogs
Since its inception over 30 years ago, the 340B drug pricing program policy has evolved allowing for unprecedented expansion and influence. With this it has also become highly contested, especially in recent years as more legislation has been put forward to close 340B loopholes.